BioNet is a biotech company focusing on bio-innovation and access to genetically-designed vaccines.

BioNet is the world’s only manufacturer of licensed recombinant pertussis vaccines containing a genetically-inactivated pertussis toxin (PTgen).

BioNet’s vision to forge global product partnerships has led to the rapid development of genetic vaccines using DNA and mRNA technology platforms. Clinical development of BioNet COVID-19 DNA candidate vaccines are conducted in Australia by Technovalia and partners. BioNet has been manufacturing a mRNA COVID-19 vaccine developed by Chulalongkorn University and the University of Pennsylvania.

BioNet is now developing a pancoronavirus mRNA vaccine with the support from CEPI. BioNet is leading a global consortium composed of US and Thai universities and the International Vaccine Institute.

BioNet’s main locations are Bangkok, Thailand and Lyon, France with a vaccine manufacturing plant in Ayutthaya, Thailand. Our team of more than 200 people across the globe are fully dedicated to the development, manufacturing and supply of vaccines against re-emerging and pandemic diseases.